{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:06:44Z","timestamp":1791356804766,"version":"4.3.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020132","name":"Anthos Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014607","name":"Royal Children's Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rpth.2026.103446","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:46:02Z","timestamp":1774543562000},"page":"103446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The in vitro anticoagulant effect of abelacimab in healthy children"],"prefix":"10.1016","volume":"10","author":[{"given":"Natasha","family":"Letunica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Collett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Karlaftis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Khder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Freedholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Monagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4428-1663","authenticated-orcid":false,"given":"Chantal","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103446_bib1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","article-title":"Assessing bleeding risk in patients taking anticoagulants","volume":"35","author":"Shoeb","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2026.103446_bib2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/asheducation-2018.1.399","article-title":"Management of thrombosis in children and neonates: practical use of anticoagulants in children","volume":"2018","author":"Monagle","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2026.103446_bib3","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1016\/S2352-3026(24)00281-3","article-title":"Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants","volume":"11","author":"Ageno","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.103446_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.860369","article-title":"Practical considerations for use of direct oral anticoagulants in children","volume":"10","author":"Whitworth","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.rpth.2026.103446_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103446_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100140","article-title":"What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?","volume":"7","author":"Betensky","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103446_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpeds.2021.09.025","article-title":"Direct oral anticoagulants: overcoming the challenges of managing venous thromboembolism in children","volume":"240","author":"Male","year":"2022","journal-title":"J Pediatr"},{"key":"10.1016\/j.rpth.2026.103446_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100094","article-title":"Physical activity for children with deep vein thrombosis and pulmonary embolism on anticoagulation: a scoping review","volume":"7","author":"Bastas","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103446_bib9","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103446_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103446_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4143980","article-title":"Abstract 4143980: Bleeding with the FXI inhibitor abelacimab compared with rivaroxaban in patients on antiplatelet therapy: a prespecified analysis of the AZALEA-TIMI 71 trial","volume":"150","author":"Al Said","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2026.103446_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2024.100179","article-title":"Abelacimab: a leap forward in anticoagulation with FXI and FXIa Inhibition","volume":"6","author":"Badreldin","year":"2024","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.rpth.2026.103446_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.thromres.2012.07.009","article-title":"The in vitro anticoagulant effect of rivaroxaban in children","volume":"130","author":"Attard","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103446_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MBC.0000000000000033","article-title":"The in-vitro anticoagulant effect of rivaroxaban in neonates","volume":"25","author":"Attard","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2026.103446_bib15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2010.08163.x","article-title":"Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children","volume":"149","author":"Ignjatovic","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.103446_bib16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.thromres.2005.11.004","article-title":"Age-related differences in heparin response","volume":"118","author":"Ignjatovic","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103446_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.thromres.2020.05.020","article-title":"Age-specific differences in the in vitro anticoagulant effect of bivalirudin in healthy neonates and children compared to adults","volume":"192","author":"Letunica","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103446_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025897","article-title":"A prospective, cross-sectional study to establish age-specific reference intervals for neonates and children in the setting of clinical biochemistry, immunology and haematology: the HAPPI Kids study protocol","volume":"9","author":"Hoq","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.rpth.2026.103446_bib19","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103446_bib20","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/ajcp\/82.4.436","article-title":"Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies","volume":"82","author":"Marlar","year":"1984","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.rpth.2026.103446_bib21","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/jth.12372","article-title":"Developmental hemostasis: age-specific differences in the levels of hemostatic proteins","volume":"11","author":"Attard","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103446_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-01-0047","article-title":"Developmental haemostasis: impact for clinical haemostasis laboratories","volume":"95","author":"Monagle","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103446_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109564","article-title":"The in vitro anticoagulant effect of milvexian in healthy neonates and children","volume":"257","author":"Letunica","year":"2026","journal-title":"Thromb Res"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926001044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926001044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:16:11Z","timestamp":1790723771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926001044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2475037926001044"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103446","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The in vitro anticoagulant effect of abelacimab in healthy children","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103446"}}